Global Peptide Based Metabolic Disorders Therapeutics Market: Key Facts and ForePosted by Arslan on December 10th, 2018 There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments. Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market. To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders. Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market. A metabolic disorder is a disorder which can occur due to alterations in the normal metabolic processes in the body caused by abnormal chemical reactions take place within. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability. Due to their broad range of mechanisms and activities, they can be used in the treatment of metabolic disorders. According to Fact.MR’s research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn. 5 Forecast Highlights on Global Peptide Based Metabolic Disorders Therapeutics Market
Exenatide and Others Segments Have a Tie The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022. Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017. Competition Tracking The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG. Like it? Share it!More by this author |